# Haploidentical Transplantation With CD3/CD19 Depleted Grafts in Patients With Hematologic Malignancies

> **NCT00202917** · PHASE1,PHASE2 · COMPLETED · sponsor: **University Hospital Tuebingen** · enrollment: 61 (actual)

## Conditions studied

- Hematologic Malignancies

## Interventions

- **DRUG:** Fludarabine
- **DRUG:** Thiotepa
- **DRUG:** Melphalan
- **DRUG:** OKT-3
- **PROCEDURE:** CD3/CD19 depletion on CliniMACS

## Key facts

- **NCT ID:** NCT00202917
- **Lead sponsor:** University Hospital Tuebingen
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-02
- **Primary completion:** 2009-07
- **Final completion:** 2010-12
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2014-05-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00202917

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00202917, "Haploidentical Transplantation With CD3/CD19 Depleted Grafts in Patients With Hematologic Malignancies". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT00202917. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*